Form 4: Biodesix Inc. Executive Acquires Series A Convertible Preferred Stock

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., acquired 22 shares of Series A Non-Voting Convertible Preferred Stock on April 5, 2024, pending stockholder approval for conversion into common stock.

Summary

• Chris Vazquez, the Chief Accounting Officer of Biodesix Inc., filed a Form 4 on April 9, 2024, reporting a transaction.
• On April 5, 2024, Vazquez acquired 22 shares of Series A Non-Voting Convertible Preferred Stock.
• These shares were issued under securities purchase agreements, contingent on stockholder approval at the 2024 annual meeting for conversion into common stock.
• Upon approval, each preferred share will convert into 40 common shares, subject to a 19.9% ownership limitation for Vazquez and his affiliates.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction of preferred stock issuance to an executive, contingent on future events. There are no explicit positive or negative implications at this stage.

Risks

• The conversion of the preferred stock into common stock is contingent on stockholder approval, which is not guaranteed.
• The 19.9% ownership limitation could restrict the full conversion of the preferred stock if Vazquez's ownership, including affiliates, exceeds this threshold.

Future Outlook

The future outlook depends on the stockholder approval of the conversion proposal at the 2024 annual meeting, which will determine whether the preferred stock is converted into common stock.

Industry Context

This filing reflects insider activity related to equity ownership, which is a common occurrence in publicly traded companies. It provides transparency into the holdings of key executives and their alignment with company performance.

Stakeholder Impact

• Shareholders: The conversion proposal could dilute existing shareholders if approved.
• Employees: The transaction could incentivize the Chief Accounting Officer to align with company goals.
• Company: The conversion could impact the capital structure of the company.

Next Steps

• Biodesix will submit the conversion proposal to its stockholders for approval at the 2024 annual meeting.
• Stockholders will vote on the approval of the conversion of the Preferred Stock into shares of Common Stock.

Key Dates